Chamber Approves Warning on Medications That May Impair Driving Ability
The Health Commission of the Chamber of Deputies took an important step for traffic safety by approving a project that requires warnings on the labels, package inserts, and advertising materials of medications capable of affecting the ability to drive.
The measure, which aims to raise consumer awareness about the risks of combining driving and certain medications, was included as a substitute by the rapporteur, Deputy Rogéria Santos (Republicanos-BA), to Bill 877/24, authored by Deputy Juninho do Pneu (União-RJ).
“The use of medications associated with driving can significantly increase the risk of traffic accidents,” stated the rapporteur. She emphasized that the initiative will allow consumers to make safer decisions, reducing the likelihood of accidents.
-
Better than Corolla? Used Arrizo 6 delivers luxury and turbo engine for the price of a compact
-
The BYD Tai S Ti7 bets on a boxy design and could become the top-of-the-line model in Brazil with 488 hp, over 70 kgfm of torque, 0 to 100 in 4.9 seconds, 5.1 meters in length, and a range exceeding 900 km.
-
‘All in one’: revolutionary engine comes to life with a 1.5-liter [engine] of up to 163 hp, two electric motors, and a compact hybrid system that promises to transform any electric car into a long-range hybrid
-
With a single-cylinder engine, the new Yamaha gets 80 km with 2 liters, delivers 12 hp at 8,000 rpm, features traction control, a 19% stiffer chassis, 267 mm brakes, and a 4.6-inch digital panel for around R$ 12,000.
The proposal amends Law 6.360/76, which regulates health surveillance of medications, expanding the requirements to protect drivers and pedestrians.
The wording of the approved text was carefully adjusted to include the mandatory warnings without excessively burdening the pharmaceutical industry.
The proposal reflects the growing concern for traffic safety, especially in light of frequent reports of accidents associated with the misuse of medications that impair reflexes and attention.
Next Steps in Congress
Now, the project goes for analysis, in a conclusive manner, by the Consumer Defense and Constitution, Justice and Citizenship (CCJ) commissions. If approved in these stages, it will still need to pass a vote in the Chamber and the Senate before being sanctioned and becoming law.
Despite the progress, experts warn that the effectiveness of the measure depends not only on the adoption of the warnings but also on raising public awareness and proper enforcement.
One point that raised questions was the deadline for pharmaceutical companies to adapt to the new requirements, which will still be defined in subsequent regulation. This highlights the importance of open dialogue among government, industry, and society.
With the final approval, it is expected that the initiative will contribute to the reduction of accidents related to the use of medications and driving.

Be the first to react!